While Icad has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? Icad shares have added about 7.7% since the beginning of the year versus the S&P 500's gain of 17.2%. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. The company has topped consensus revenue estimates two times over the last four quarters. This compares to year-ago revenues of $5.57 million. Icad, which belongs to the Zacks Computer - Software industry, posted revenues of $7.83 million for the quarter ended June 2021, missing the Zacks Consensus Estimate by 14.19%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. A quarter ago, it was expected that this imaging and early cancer detection company would post a loss of $0.11 per share when it actually produced a loss of $0.07, delivering a surprise of 36.36%. This quarterly report represents an earnings surprise of -37.50%. These figures are adjusted for non-recurring items. This compares to loss of $0.12 per share a year ago. Icad ( ICAD Quick Quote ICAD - Free Report) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.08.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |